Mild versus moderate stages of Alzheimer's disease: three-year outcomes in a routine clinical setting of cholinesterase inhibitor therapy

Alzheimer's Research & Therapy
Carina WattmoAsa K Wallin

Abstract

There is an increasing interest in cognitive and functional outcomes in the respective stages of Alzheimer's disease (AD) and in novel therapies particularly for the milder phases of AD. Our aim was to describe and compare various aspects of disease progression in patients with mild versus moderate AD in routine clinical practice of cholinesterase inhibitor (ChEI) therapy. This 3-year, prospective, observational, multicentre study included 1021 participants. Of these, 734 had mild AD (Mini-Mental State Examination (MMSE) score, 20-26) and 287 had moderate AD (MMSE score, 10-19) at the start of ChEI treatment. At baseline and every 6 months, patients were assessed using cognitive, global, instrumental and basic activities of daily living (ADL) scales. Potential predictors of deterioration in moderate AD were analysed using mixed-effects models. The change from baseline between participants with mild and moderate stages of AD after 3 years of ChEI therapy differed significantly on the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) and basic ADL, but not using the MMSE and instrumental ADL scales. Protective independent factors for better cognitive long-term outcome in the group with moderate AD were older age,...Continue Reading

References

Nov 1, 1975·Journal of Psychiatric Research·M F FolsteinP R McHugh
Nov 1, 1984·The American Journal of Psychiatry·W G RosenK L Davis
Jan 1, 1995·The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences·L TeriE B Larson
May 30, 1996·Statistics in Medicine·X LiuY Stern
Apr 27, 1999·JAMA : the Journal of the American Medical Association·K L DavisV Haroutunian
Jan 5, 2000·The American Journal of Psychiatry·J L Cummings
May 2, 2000·Health Care Analysis : HCA : Journal of Health Philosophy and Policy·S HolmO F Norheim
Sep 6, 2000·Dementia and Geriatric Cognitive Disorders·S Lilienfeld, W Parys
May 31, 2003·BMC Health Services Research·Shu-Chuan Jennifer Yeh, Yea-Ying Liu
Oct 21, 2004·Alzheimer Disease and Associated Disorders·Alexander KurzRené Spiegel
Dec 20, 2005·Journal of Neurology, Neurosurgery, and Psychiatry·S E StarksteinR G Robinson
Dec 17, 2009·JAMA : the Journal of the American Medical Association·Robert C GreenUNKNOWN Tarenflurbil Phase 3 Study Group
Nov 9, 2010·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Gary Small, Roger Bullock
Jan 12, 2011·Archives of Neurology·Lon S SchneiderUNKNOWN Alzheimer's Disease Neuroimaging Initiative
May 17, 2011·The American Journal of Psychiatry·Cheryl L P VigenLon S Schneider
Jul 22, 2011·Alzheimer's Research & Therapy·Carina WattmoLennart Minthon
Jan 5, 2013·Alzheimer's Research & Therapy·Carina WattmoAsa K Wallin
Jul 3, 2013·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Bruno VellasUNKNOWN EU/US/CTAD Task Force Members
Jan 24, 2014·The New England Journal of Medicine·Rachelle S DoodyUNKNOWN Solanezumab Study Group
May 20, 2014·Journal of Neurology, Neurosurgery, and Psychiatry·Ying LiuLan Tan
Sep 18, 2014·Journal of Alzheimer's Disease : JAD·Jun WangJin-Tai Yu
Mar 31, 2015·Alzheimer's Research & Therapy·Katrin JekelLutz Frölich

❮ Previous
Next ❯

Citations

Jul 27, 2017·Psychogeriatrics : the Official Journal of the Japanese Psychogeriatric Society·Shigeru SaseYutaka Sawa
Dec 5, 2017·Journal of Alzheimer's Disease : JAD·Paulami ChatterjeeNitin Rathi
Feb 7, 2019·Current Medical Research and Opinion·Fumitoshi NiwaMasanori Nakagawa
May 25, 2018·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Stefan J TeipelUNKNOWN Alzheimer Precision Medicine Initiative (APMI)
Jan 15, 2020·Advances in Therapy·Jana PodhornaSusann Walda
Oct 28, 2017·The International Journal of Neuroscience·Sutapa Som Chaudhury, Chitrangada Das Mukhopadhyay
Feb 15, 2020·Journal of Geriatric Psychiatry and Neurology·Clarissa M GiebelMizanur Khondoker
Jan 29, 2019·Journal of Alzheimer's Disease : JAD·Alice L LaElissaios Karageorgiou
Jan 12, 2020·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Hussein AkelIldikó Csóka
Dec 12, 2020·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Zeinab Breijyeh, Rafik Karaman

❮ Previous
Next ❯

Software Mentioned

Statistical Package for the Social Sciences ( SPSS )

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Alzheimer's Disease: APOE

Apolipoprotein E (APOE) polymorphic alleles are major genetic risk factors for Alzheimer's disease. Discover the latest research on APOE and other genetic determinants of Alzheimer's disease here.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here

ApoE Phenotypes

Apolipoprotein E (APOE) is a protein involved in fat metabolism and associated with the pathogenesis of Alzheimer's disease and cardiovascular disease. Here is the latest research on APOE phenotypes.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here